Antibody Analytics is thrilled to announce that we have been shortlisted in Scotland's Life Sciences Annual Awards in the 'Innovation Pharma Services and Drug Discovery' category.
At Antibody Analytics, we advance the discovery and development of novel immunotherapies and biologics through the development of innovative technologies to provide an industry-leading service to our global clients. We are passionate about pushing boundaries and finding solutions to the challenges facing developers of advanced therapeutics. Becoming a finalist in this category is the direct result of our amazing employees and our commitment to sustained research and development.
Andy Upsall, Managing Director of Antibody Analytics, said:
"It is awesome to have been shortlisted in Scotland's Life Sciences Annual Awards in the Innovation Pharma Services and Drug Discovery category. At Antibody Analytics, we place a huge emphasis on driving innovation within our organisation. Identifying new ways to support the discovery, development and delivery of advanced therapeutics and immunotherapies is in our DNA.
"With the increasing requirement to apply relevant in vitro disease models at early stages of drug discovery, we are leading the way with a suite of primary cell assay platforms that faithfully model the tumour microenvironment, providing our clients with high content, decision-making data that will accelerate their route to the clinic. We are committed to enabling our partners to move faster, with greater efficiency through the drug discovery and development process. Our shortlisting is a testament to our team's hard work and dedication.
"We are delighted to be recognised in this innovation category and this further motivates our team to continue to strive for excellence and deliver the best results possible for our partners. We are immensely proud and look forward to continuing to make a difference in the global life sciences industry."
We want to thank all our partners, clients, and colleagues for their continued support. We are committed to continuing to drive technological innovation in the immunotherapy sector and will strive to discover new ways of advancing drug discovery and development.